Immune cell therapy targets rare inflammatory disease

NCT ID NCT07061938

First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 18 times

Summary

This early-stage trial tests a new cell therapy called ACE1831 for people with IgG4-Related Disease, a rare condition causing inflammation in multiple organs. The therapy uses immune cells from healthy donors to potentially control the disease. About 30 adults with active flares will receive the treatment, and researchers will monitor safety and whether symptoms improve. This is not a cure, but aims to manage the disease long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGG4-RELATED DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Kanazawa Medical University Hospital

    RECRUITING

    Kahoku-gun, JP, 920-0293, Japan

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.